Axiom Investors LLC DE Acquires 1,915 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Axiom Investors LLC DE boosted its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 6.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 30,110 shares of the company’s stock after acquiring an additional 1,915 shares during the quarter. Axiom Investors LLC DE’s holdings in Syndax Pharmaceuticals were worth $630,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. ExodusPoint Capital Management LP purchased a new position in shares of Syndax Pharmaceuticals during the first quarter valued at approximately $1,307,000. Exchange Traded Concepts LLC grew its stake in shares of Syndax Pharmaceuticals by 740.7% in the 2nd quarter. Exchange Traded Concepts LLC now owns 7,213 shares of the company’s stock worth $151,000 after acquiring an additional 6,355 shares in the last quarter. Panagora Asset Management Inc. raised its holdings in shares of Syndax Pharmaceuticals by 1.8% in the first quarter. Panagora Asset Management Inc. now owns 182,381 shares of the company’s stock valued at $3,852,000 after purchasing an additional 3,296 shares during the last quarter. PAX Financial Group LLC bought a new position in shares of Syndax Pharmaceuticals during the first quarter valued at about $501,000. Finally, Jennison Associates LLC boosted its holdings in Syndax Pharmaceuticals by 4.4% during the second quarter. Jennison Associates LLC now owns 2,521,916 shares of the company’s stock worth $52,784,000 after purchasing an additional 105,462 shares during the last quarter.

Syndax Pharmaceuticals Price Performance

NASDAQ:SNDX opened at $15.42 on Tuesday. The company has a market cap of $1.07 billion, a P/E ratio of -5.98 and a beta of 1.04. Syndax Pharmaceuticals, Inc. has a 1 year low of $11.22 and a 1 year high of $29.86. The stock’s fifty day moving average price is $14.08 and its two-hundred day moving average price is $18.09.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SNDX. StockNews.com assumed coverage on Syndax Pharmaceuticals in a research note on Thursday, October 5th. They issued a “sell” rating on the stock. Robert W. Baird decreased their target price on Syndax Pharmaceuticals from $32.00 to $28.00 in a research report on Tuesday, October 3rd. Stifel Nicolaus lowered their target price on Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, October 26th. Guggenheim increased their price target on shares of Syndax Pharmaceuticals from $42.00 to $43.00 in a research report on Tuesday, October 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Syndax Pharmaceuticals from $36.00 to $38.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 17th. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.09.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).